Orexigen Therapeutics, Inc. (NASDAQ:OREX)

Orexigen, Advaxis Tumble into Tuesday’s 52-Week Low Club

March 13, 2018: Here are four stocks trading with heavy volume among 36 equities making new 52-week lows in Tuesday's session. On the NYSE decliners led advancers by about 3 ...
Read Full Story »

Anthera, Orexigen Submerge in Monday’s 52-Week Low Club

March 12, 2018: Here are four stocks trading with heavy volume among 39 equities making new 52-week lows in Monday's session. On the NYSE advancers led decliners by around 8 ...
Read Full Story »
Jon's friends

Wednesday’s Top 5 Biopharma Movers

Biotech and pharma companies were on the move Wednesday. A few made absolutely massive gains on the day, giving more credence to the Trump rally and positive sentiment for the health care ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Chipotle, Oracle, Orexigen, PulteGroup, Reynolds American, Valeant and More

Stocks were directionless on Wednesday ahead of the Federal Reserve's decision on interest rates. With the Dow over 17,250 and the S&P 500 at 2,015, the markets are almost flat ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Huntington Bancshares, Nucor, Orexigen, SanDisk, Square, VIVUS and Many More

Stocks were indicated to open lower on Monday morning, but that is after two weeks of a rally. Is it possible that the trend of selling into every rally is ...
Read Full Story »
ThinkstockPhotos-529331537

Orexigen Therapeutics Receives $15 Million Milestone Payment

Orexigen Therapeutics Inc. (NASDAQ: OREX) made waves in the market early on Wednesday, despite the sell-off on Tuesday. The company announced receipt of the first of three potential $15 million ...
Read Full Story »
153576724

Are Problems at Orexigen Still Just Getting Started?

Orexigen Therapeutics Inc. (NASDAQ: OREX) had to bite the bullet Tuesday when it announced that it would be terminating its cardiovascular outcomes study of the obesity drug Contrave. However, things ...
Read Full Story »
ten dollar bills

8 Analyst Stocks Under $10 With Huge Upside Targets

The last full week of March was choppy and took away most of the 2015 gains for the Dow and the S&P. Still, investors keep looking for value, and the ...
Read Full Story »
Biotechnology word cloud

Wells Fargo’s Top Biotech Stocks for 2015

Looking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo ...
Read Full Story »
153576724

Is Orexigen Really Worth Over 50% More?

Merrill Lynch has released an analyst report that sees more than 50% upside for Orexigen Therapeutics Inc. (NASDAQ: OREX). The top analyst on the call was Steve Byrne, and the general ...
Read Full Story »
research

Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential

While Friday was a welcome relief for shell-shocked stock investors, much of the damage that has been inflicted since the start of the quarter is still weighing on some top ...
Read Full Story »
ten dollar bills

9 Analyst Stocks to Buy Under $10 With Massive Upside Potential

With stocks at or close to all-time highs, many investors are looking for new ideas and other stocks that may be lesser known than other big names. 24/7 Wall St. ...
Read Full Story »
biotech

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm. The biotech sector has been a wealth-creation engine in recent years. What is interesting here ...
Read Full Story »
buy sell

Twelve Analyst Stocks Trading Under $10 With Huge Implied Upside

Stocks have pulled back from their all-time highs after escalation of civil war in Iraq, but Friday managed to close higher. Investors remain bullish, and they keep hearing that the ...
Read Full Story »
thumbs up

Three Analyst Stocks Projected to Double, or More

Every week at 24/7 Wall Street we see the research reports from many firms across Wall Street, and we are always sifting through the mounds of data looking for the ...
Read Full Story »